**Spatial transcriptomic validation** of a biomimetic model of fibrosis enables re-evaluation of a therapeutic antibody targeting LOXL2

Joseph A Bell1,2,Elizabeth R Davies1,2,3, Christopher J Brereton1,2, Milica Vukmirovic4,5, James JW Roberts6, Kerry Lunn6, Leanne Wickens1,2,7, Franco Conforti1,2, Robert A Ridley1,2, Jessica Ceccato1,8, Lucy N Sayer1,2 , David A Johnston9, Andres F. Vallejo1, Aiman Alzetani2,10, Sanjay Jogai10, Ben G Marshall2,10, Aurelie Fabre11, Luca Richeldi1,2,12, Phillip D Monk6, Paul Skipp2,3,10, Naftali Kaminski4, Emily Offer13, Yihua Wang2,3,7, Donna E Davies1,2,7, Mark G Jones1,2,7,14\*.

1Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK.

2NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton SO16 6YD, UK.

3Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton SO17 1BJ, UK.

4Section of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Yale University School of Medicine, New Haven, United States

5 Leslie Dan Faculty of Pharmacy, University of Toronto

6Synairgen Research Ltd, Southampton, United Kingdom

7Institute for Life Sciences, University of Southampton, Southampton SO17 1BJ, UK.

8Department of Medicine, University of Padova, Padova, Italy

9Biomedical Imaging Unit, Faculty of Medicine, University of Southampton, Southampton, UK

10University Hospital Southampton, Southampton SO16 6YD, UK.

11Department of Histopathology, St. Vincent's University Hospital & UCD School of Medicine, University College Dublin, Dublin, Ireland

12Unità Operativa Complessa di Pneumologia, Università Cattolica del Sacro Cuore, Fondazione Policlinico A. Gemelli, Rome, Italy.

13Medicines Discovery Catapult, Alderley Edge, UK

14Lead Contact

\*Correspondence should be addressed to MGJ (mark.jones@soton.ac.uk)

# SUMMARY

Matrix stiffening by lysyl oxidase-like 2 (LOXL2) mediated collagen cross-linking is proposed as a core feed-forward mechanism that promotes fibrogenesis. Failure in clinical trials of simtuzumab (the humanized version of AB0023, a monoclonal antibody against human LOXL2) suggested targeting LOXL2 may not have disease relevance, however target engagement was not directly evaluated. We compare the spatial transcriptome of active human lung fibrogenesis sites with different human cell culture models to identify a disease-relevant model. Within the selected model, we then evaluate AB0023, identifying that it does not inhibit collagen cross-linking or reduce tissue stiffness, nor does it inhibit LOXL2 catalytic activity. In contrast it does potently inhibit angiogenesis consistent with an alternative, non-enzymatic mechanism of action. Thus, AB0023 is anti-angiogenic but does not inhibit LOXL2 catalytic activity, collagen cross-linking or tissue stiffening. These findings have implications for interpretation of lack of efficacy of simtuzumab in clinical trials of fibrotic diseases.

**KEYWORDS**: Fibrosis; spatial transcriptomics; disease relevant biomimetic models; LOXL2; target engagement

# INTRODUCTION

Fibrotic diseases are a major cause of morbidity and mortality in the developing world. Within the lung, idiopathic pulmonary fibrosis (IPF) is considered the prototypic chronic progressive fibrotic disease1. Treatment options are limited, and with a median survival of less than 3 years from diagnosis, more effective therapies are urgently needed. Whilst the exact mechanisms are uncertain, progressive lung fibrosis is believed to result from repetitive micro-injuries to the alveolar epithelium promoting aberrant fibroblast activation into matrix-producing myofibroblasts.1 These myofibroblasts deposit extracellular matrix (ECM) components which eventually destroy normal alveolar architecture with consequent disruption of gas exchange. Pathogenic ECM changes have been strongly implicated in fibrosis progression, with resulting increased matrix stiffness proposed to induce persistent mesenchymal cell activation and hence fibrosis progression in a positive feedback loop.2–7

A defining feature of human idiopathic pulmonary fibrosis (usual interstitial pneumonia pattern) is spatial heterogeneity, with normal lung adjacent to histologically evident established fibrosis. At the interface between fibrosis and morphologically normal lung are fibroblast foci; our own studies and those of others evidence they reflect discrete sites of active fibrogenesis.8–10 Importantly the density of fibroblast foci is the histologic feature most consistently associated with disease progression,11–13 consistent with their having a key pathogenetic role in lung fibrosis, with histological studies identifying them to be mesenchymal cells which are synthesising altered extracellular matrix. Thus, increased understanding of fibroblast foci and their in vitro recapitulation provides the opportunity to dissect key aspect(s) of progressive human lung fibrogenesis.

 Fibrillar collagens are a major component of ECM that form a scaffold to support tissue architecture and are a primary determinant of tissue stiffness in health and disease.14,15 The tensile properties of collagen fibrils result from intermolecular crosslinks connecting the nonhelical ends of a collagen molecule (telopeptides) with the triple helical part of an adjacent molecule.16,17 The lysyl oxidase (LOX) enzymes are a family of five secreted copper-dependent amine oxidases that are responsible for post-translational modification of collagen in the ECM by initiating this covalent cross-linking process. LOX enzymes convert specific lysine or hydroxylysine residues in the telopeptides into the aldehydes allysine and hydroxyallysine, respectively.18 The aldehydes subsequently react with lysine, hydroxylysine or histidyl, residues of the triple helix to give characteristic di-, tri-, and tetrafunctional crosslinks. Crosslinking is essential to stabilise the supramolecular assembly of collagen and produce stable collagen fibrils. Dysregulation of LOX family member expression has been identified across many disease areas,19 with increased mature trivalent pyridinoline (PYD) hydroxyallysine-derived collagen cross-links altering collagen nano-architecture and increasing tissue stiffness in human lung fibrosis.15

Lysyl oxidase-like 2 (LOXL2) mediated collagen cross-linking has been proposed as a core pathway of fibrogenesis in multiple fibrotic diseases including the lung, heart, and liver.20,21 Within the lung, LOXL2 is highly expressed within fibroblastic foci, the sites of active fibrogenesis,22 whilst elevated LOXL2 levels in serum have been associated with increased risk for IPF disease progression in two cohorts of patients.23 AB0023, a monoclonal antibody against human LOXL2 protein, showed efficacy in the bleomycin mouse model of lung fibrosis as well as in preclinical models of liver fibrosis and cardiac fibrosis.20,21 However, simtuzumab (the fully humanised version of AB0023) failed to achieve positive clinical endpoints in multiple fibrotic diseases including IPF.24–26 Importantly, no direct evidence of target engagement in these studies was measured, triggering uncertainty about the reason for the lack of efficacy in humans. Furthermore, whilst AB0023 was proposed in preclinical studies to partially inhibit LOXL2-mediated enzymatic activity, this was based on measurement of amine oxidase activity in cell free biochemical assays,27 however no direct biochemical measurement of inhibition of collagen crosslinking was performed.20,27 Thus, in the absence of direct assessment of molecular mechanism of action (i.e. inhibition of collagen crosslinking activity), the impact of Simtuzumab/AB0023 on pathological tissue stiffening is still unknown.

 Multiple animal models of lung fibrosis have been developed, however, significant numbers of proposed therapies with demonstrated efficacy in animal studies have translated into ineffective or even harmful actions in clinical studies.28–30 Importantly, the most commonly used murine model of bleomycin-induced lung fibrosis does not recapitulate key features of human lung fibrogenesis including increased mature PYD cross-linking31 and so cannot be used to dissect key factors promoting altered collagen crosslinking in human disease. To reduce the attrition rate of new drugs, greater emphasis is therefore being placed on *in vitro* human cell-based biomimetic models which may better recapitulate human disease.32 For cellular models of fibrosis, matrix-producing fibroblasts are typically cultured as monolayers on standard tissue culture plastic, however substrate stiffness, composition, and structure are known to influence cell behaviour and phenotype.33 Advanced 3D cell culture methodologies using disease relevant cells have therefore been proposed to better reproduce the complex cell-cell and cell-ECM environment of human lung fibrosis34 but only limited validation of the disease relevance of such approaches has been performed.

 Recent advances in RNA sequencing and spatial transcriptomic approaches provides the opportunity to characterise gene expression profiles within distinct regions of the fibrotic niche including cell populations and key regulatory pathways active within areas of active fibrogenesis.35,36 The spatial transcriptome of the fibrotic niche can then be compared with *in vitro* culture model systems to identify models with most disease relevance.

 Here, we compared the spatial transcriptome of fibroblast foci with cell culture-based models to identify the *in vitro* model that most closely recapitulates the gene expression profile of human fibroblast foci. We then investigated directly the efficacy of AB0023 upon collagen cross-linking and tissue stiffness within this model.

# RESULTS

***Enrichment of a skeletal development signature within fibroblastic foci***

We firstly studied the spatial transcriptomic profiles of fibroblast foci which are the sites of active fibrogenesis in IPF. We analysed a data set we recently generated by integrating laser-capture-microdissection and RNA-Seq (LCMD/RNA-seq) to profile the *in situ* transcriptome of fibroblast foci as well as alveolar septae from control tissue and IPF tissue.22 We confirmed biologically plausible clustering of each region of interest by principal components analysis (Figure 1A), with this most apparent for fibroblast foci, which cluster together distant from the alveolar septae samples. We then confirmed enrichment of key mesenchymal associated genes within the fibroblastic foci including *ACTA2* (Figure 1B) as well as matrisomal genes including *TNC, COL1A1 and COL5A1* (Figure 1C-E). In contrast, the Type 2 Alveolar epithelial gene *SFTPC* was significantly reduced within fibroblast foci (Figure 1F) when compared with alveolar septae.

 In order to dissect gene sets enriched in the fibroblast foci, Gene Set Variation Analysis (GSVA) was performed. We identified a strong enrichment for gene ontology terms associated with collagen fibril organisation and bone morphogenesis within fibroblast foci (Figure 1G-I, File S1), a finding in keeping with our recent spatial analysis of gene expression profiles of fibroblast foci through digital spatial profiling.36

***A 3D spheroid model most closely resembles the transcriptome of human fibroblast foci***

To translate the insights from our clinical sample analysis, we performed cell culture studies. In order to determine a model of fibrogenesis that can best represent human fibroblast foci, we compared the transcriptome of fibroblast foci with 3 primary human lung parenchymal fibroblast cell culture models using their standard culture conditions in the presence or absence of the profibrotic cytokine TGF-β1: (i) A 2D model of primary lung fibroblasts grown on standard tissue culture plasticware;37 (ii) A pseudo-3D Scar-In-A-Jar model using macromolecules to provide crowding conditions proposed to more closely resemble the fibrotic microenvironment and promote collagen deposition;38 (iii) A long term 3D spheroid model which self-assembles a 3D extracellular matrix with a progressive increase in collagen content and which we have previously demonstrated enables direct evaluation of pyridinoline cross-linking, collagen nanostructure, and tissue biomechanics.15 For each culture model, a second timepoint (2 weeks) was included to allow for overlap of culture duration. An overview of the study design is presented in Figure 2A, and example microscopy images of each model in Figure 2B.

To compare these different culture models to fibroblastic foci, we performed Gene Set Variation Analysis (GSVA) on a combined dataset of the transcriptome of fibroblastic foci and of each cell culture model. Unsupervised hierarchical clustering of GSVA scores for the most variable gene ontology terms (Kruskal-Wallis test, p<0.01) identified that the 3D spheroid model clustered together with fibroblast foci (Figure 2C), with the greatest similarity between fibroblast foci and the 3D spheroid model in the presence of TGF-β1. This condition exhibited expression patterns involving morphology (GO\_Actin\_Filament) (Figure 2D), signalling pathways (GO\_Chemokine\_Activity & GO\_Non-canonical\_Wnt\_Signalling\_Pathway) (Figure 2E-F), and metabolism(GO\_Tricarboxylic\_Acid\_Cycle) (Figure 2G), as well as pathways associated with bone morphogenesis (GO\_Osteoclast\_Proliferation) (Figure 2H) similar to those enriched within our spatial transcriptomic analysis of fibroblast foci. In contrast, the Scar-In-A-Jar and 2D culture models clustered together (Figure 2C), with distinct subclusters of each model and time point in the absence or presence of TGF-β1.

To understand which gene expression patterns within the 3D spheroid model may support the similarity with the fibroblast focus transcriptome we performed analysis of significantly (adjusted p value < 0.05) differentially expressed genes (Figure 3A). When subjected to enrichment analysis, upregulated gene sets within the 3D spheroid model in the presence of TGF-β1 included those associated with protein hydroxylation, peptidyl-lysyl hydroxylation, and extracellular matrix organisation (Figure 3B-E and File S1). Genes upregulated within the 3D spheroid model when compared to the other model systems included fibrillar collagens (*COL3A1*) as well as genes previously proposed to have pathogenic roles in promoting progressive fibrosis through dysregulation of the extracellular matrix microenvironment including collagen prolyl hydroxylase activity (*P4HA3*), bone-type pyridinolone collagen cross-linking (*PLOD2*), hyaluronan synthesis (*HAS1*), and pro-fibrotic fibroblast activation (*TWIST1*) (Fig 3E-G).22,39–41

To further investigate the similarities and differences between each model system we performed analysis of secreted cytokines within conditioned media from each model. We assayed cytokines and mediators previously proposed to have roles in lung fibrogenesis including modulators of chemotaxis, extracellular matrix remodelling, and inflammation.42–57 From a recent large scale proteomic analysis of IPF survival by Oldham et al.58 we identified those secreted factors significantly associated with increased risk of death or transplant. Of the identified molecules, the 3D cell culture-based model had the greatest expression (TIMP1, VEGFA) or comparable expression (GDF-15, OPN, CCL2, POSTN, TNC) of each secreted factor (Figure S1) compared with the other models.

***The 3D spheroid model has similarities with the proteome of fibroblast foci***

Having identified that the 3D spheroid model has the greatest similarity to the transcriptome of fibroblast foci and secreted proteins associated with increased risk of death, to further investigate the disease relevance of the model we performed proteomic analyses of lung fibroblasts from patients with IPF cultured within the 3D spheroid model. We performed mass spectrometry (UPLC-HDMSE) analysis of the 3D spheroid model and its secretome and compared this with a recently published dataset of the fibroblast focus proteome.59 We identified diverse extracellular matrix proteins within the 3D spheroid model including multiple fibrillar collagens. Comparing the fibroblast focus proteome as quantified by Herrera et al. to the 3D model we identified clear overlap with 88 extracellular matrix associated proteins in common (Figure 4A & File S2), with an interaction network for these proteins (Figure S2) identifying a complex extracellular matrix interactome and G:Profiler analysis (Figure 4B) identifying the most significant Biological Process Gene Ontology terms to include extracellular matrix organisation and negative regulation of proteolysis. Additionally, we identified proteins that were only present in the 3D model or the fibroblast focus proteome (Fig 4c & File S2). While this may partly reflect technical differences between the mass spectrometric methods used, proteins such as cartilage oligomeric matrix protein and periostin which were not reported within the fibroblast focus proteome were detected within the 3D model consistent with their mRNA expression within fibroblast foci in our spatial transcriptomics and with protein expression previously confirmed by others.36,60,61

Further comparison with the proteomic survival dataset of Oldham et al identified that 48 proteins present in the 3D Spheroid model were significantly associated with increased risk of death or transplant (File S2). An interaction network for these risk proteins is shown in Figure 4D, with matrix metalloproteinases, elastin, and adhesion molecules serving as central hubs and pathway analysis (Figure 4E) identifying collagen-containing extracellular matrix to be the most enriched pathway.

Immunohistochemistry confirmed expression of proteins identified within our spatial transcriptomic analyses (Figure 1) including tenascin-C (Figure 4F) as well as procollagen type 1 (Figure 4G) in comparable patterns between the 3D model and fibroblast foci (Figure 4F-G). Additionally we confirmed expression of proteins by Luminex multiplex assay of cell conditioned media including TIMP-1, periostin, and tenascin-C (Figure S1). Consistent with the 3D spheroid model recapitulating a complex ECM, transmission electron microscopy confirmed the incorporation of a complex 3D extracellular matrix including fibrillar collagens (Figure 4H-I).

***The anti-LOXL2 antibody AB0023 does not inhibit LOXL2 catalytic activity, collagen cross-linking or tissue stiffness in a disease relevant model of fibrosis***

Having confirmed that the 3D spheroid model recapitulates transcriptomic and protein characteristics of fibroblast foci, we proceeded to re-evaluate the potential of LOXL2 as a therapeutic target in lung fibrosis.

Previous studies have proposed that LOXL2 expression is increased within blood and lung tissue compartments of patient with lung fibrosis.15,22,23,62 Consistent with these findings we identified a significant increase in LOXL2 expression within serum sampled at time of diagnosis of patients with IPF when compared to control subjects (Figure 5A), whilst assessing *LOXL2* expression within our recently generated digital spatial transcriptome of human control and fibrotic lung tissue36 we identify significantly increased expression within fibroblast foci (Figure 5B). This finding is in keeping with our previous identification that the greatest expression of *LOXL2* is within mesenchymal cells within fibroblast foci,22 and that *LOXL2* is co-expressed with *PLOD2* which catalyses telopeptide lysine hydroxylation to determine pyridinoline collagen cross-linking. Using RNAscope *in situ* hybridisation we therefore confirmed *LOXL2* expression within the spheroid model and that this is co-expressed with *PLOD2* in a pattern comparable to that identified within fibroblast foci (Figure 5C).

We next compared the effects of the anti LOXL2 antibody, AB0023 (a monoclonal antibody against human LOXL2 which was humanized to create simtuzumab),26,27 within the 3D spheroid model using the small molecule inhibitor PXS-S2A63 as a positive control. We have previously identified that PXS-S2A at LOXL2 selective doses inhibits pyridinoline collagen cross-linking and reduces tissue stiffness within the 3D spheroid model, confirming findings within an *in vivo* rat model of lung fibrosis driven by transient overexpression of active TGF-β1 by adenoviral vector gene transfer,15

Lung fibroblasts from patients with IPF were cultured in the 3D Spheroid model in the presence of AB0023 or an isotype control antibody at the same concentrations, as well as with PXS-S2A or its vehicle control. As previously reported,15 after 6 weeks of culture, PXS-S2A significantly reduced pyridinoline crosslinking (Figure 5D) and tissue stiffness (Figure 5E) without affecting total collagen content (Figure 5F). In contrast, there was no significant difference between AB0023 and control antibody in pyridinoline crosslinking, tissue stiffness nor collagen content (Figure 5D-F). As we had found no effect of AB0023 upon collagen cross-linking or tissue stiffness, we measured LOXL2 catalytic activity within the conditioned media using an activity-based probe64 identifying that AB0023 did not significantly inhibit LOXL2 catalytic activity whilst PXS-S2A did (Figure 5G). Nonetheless, in the presence of AB0023 we detected a decrease in VEGFA and fibronectin, two secreted proteins which have been reported as being regulated by LOXL265,66 (Figure 5H-I). In contrast, in the presence of PXS-S2A we identified an increase in VEGFA and no effect on fibronectin, suggesting distinct mechanisms of action of PXS-S2A and AB0023, and that the observed effects of AB0023 are not via catalytic inhibition. Consistent with PXS-S2A having an antifibrotic effect, we identified a reduction in the expression of profibrotic genes including *COL3A1*, *PLOD2*, *P4HA3*, and *TWIST1* (Figure S3).

***AB0023 is a potent inhibitor of angiogenesis***

AB0023 is proposed to be an allosteric inhibitor of LOXL2 catalytic activity, with the binding epitope mapped to the scavenger receptor cysteine-rich (SRCR) domain four of human LOXL227. Independent of catalytic amine oxidase activity, the SRCR domains of LOXL2 have been reported to promote angiogenesis.67 As AB0023 has previously been reported in pre-clinical cancer studies to be anti-angiogenic,68 we investigated the functional effect of the antibody on angiogenesis to exclude the possibility that our inability to detect any significant effect of AB0023 on LOXL2 catalytic activity, pyridinoline collagen crosslinking, and tissue stiffness was not due to loss of antibody efficacy.

We therefore evaluated the effect of AB0023 within a human endothelial tube formation assay.69 In the presence of AB0023 we observed a significant decrease in tube formation (Figure 6A), with quantification of topological parameters identifying a significant decrease in number of loops, number of branching points and total tube length (Figure 6B-D). In contrast, the small molecule inhibitor PXS-S2A did not significantly decrease measures of tube formation, consistent with distinct mechanisms of action of these two agents (Figure S4).

Together, these results identify that whilst AB0023 is a potent inhibitor of angiogenesis it does not significantly inhibit LOXL2 catalytic activity, collagen cross-linking or tissue stiffness in a human disease relevant model of fibrosis.

# DISCUSSION

Tissue from patients with lung fibrosis shows marked heterogeneity of pathological changes which challenges its study and modelling. Fibroblast foci are considered the site of active fibrogenesis however until recently their microenvironment has been poorly understood. Here we identify that an *in vitro* 3D spheroid model closely resembles the transcriptome of human fibroblast foci, further confirming disease relevance through proteomic comparisons. We then investigated within the model whether the anti-LOXL2 monoclonal antibody AB0023 could inhibit the ability of LOXL2 to catalyse collagen crosslinking and so reduce tissue stiffness. In these assays, AB0023 did not inhibit catalytic activity, collagen crosslinking or reduce tissue stiffness, however in endothelial tube formation assays it was a potent inhibitor of angiogenesis, consistent with a mechanism of action independent of lysyl amine oxidase inhibition. These findings have relevance to the interpretation of the failure of simtuzumab/AB0023 to demonstrate efficacy in clinical trials of fibrotic diseases where it was expected to inhibit collagen crosslinking and reduce tissue stiffening.

 The importance of human disease relevant models of complex diseases such as lung fibrogenesis is increasingly proposed for pre-clinical studies where drug attrition rates are high and translation is challenging.32 However, whilst different cell model systems have been utilized, there has been limited validation. Within human lung fibrogenesis the fibroblast focus represents a key site of disease activity. Here, advances in spatial biology approaches provided the opportunity to better characterise fibroblast foci and so compare the relevant human disease microenvironment with model systems. Bioinformatic analysis of standard 2D cell culture, the Scar-in-a-Jar model, and the 3D spheroid model identified that the 3D spheroid model has significant transcriptomic similarity with fibroblast foci. These data support the importance of 3D models incorporating extracellular matrix to understand biological phenomena.70–72 The finding of comparable expression patterns within the model to human lung fibrogenesis suggests that mechanistic and therapeutic studies within the model have translational relevance to human lung fibrosis. Consistent with this we have recently demonstrated within the 3D spheroid model that promotion of pyridinoline collagen cross-linking recapitulates key features identified within human lung fibrosis tissue including altered collagen nano-architecture and increased tissue stiffness.15,22 Our identification of enrichment of a skeletal development signature within fibroblastic foci is consistent with the shift from a skin (allysine-derived) to a bone-type (hydroxyallysine-derived) of collagen cross-link being of pathogenetic importance in human lung fibrosis. Whilst our studies have focussed upon recapitulation of fibroblast foci, ongoing the rapid advances in high resolution spatial ‘omics approaches provides the possibility of future refinement of this approach to include other disease-relevant cell types within the entire fibrotic niche.

 Human tissue and blood analyses as well as preclinical *in vitro* and *in vivo* studies have implicated LOXL2 as a core mediator of human fibrogenesis, with LOXL2 mediated collagen cross-linking increasing tissue stiffness and promoting fibrosis progression. However, the failure of simtuzumab/AB0023 to demonstrate efficacy in clinical trials of fibrotic diseases has raised uncertainty regarding the relevance of LOXL2 as a therapeutic target. AB0023 was generated by immunization of mice using human LOXL2 protein and characterized as a partial non-competitive allosteric inhibitor of LOXL2 catalytic activity.27 A subsequent *in vivo* preclinical study of fibrosis and cancer reported that there was a significant reduction in collagen cross-linking following AB0023 treatment,20 consistent with AB0023 acting via inhibition of catalytic activity. However, no direct biochemical quantification of collagen cross-linking was performed, with the reduction in collagen cross-linking inferred through quantification in the signal of polarized Sirius Red staining of tissue samples. A strong linear anionic dye, Sirius Red stains collagen by reacting, via its sulphonic acid groups, with basic groups present in the collagen molecule, so enhancing their natural birefringence under cross-polarized light.73,74 Whilst Sirius Red staining under cross-polarized light has been widely adopted as a method to assess collagen tissue deposition patterns, to our knowledge no relationship between Sirius Red quantification and collagen cross-linking density has been demonstrated. In keeping with this in our own second harmonic generation (SHG) study of collagen macro/supramolecular changes following collagen cross-linking modulation, we identified that no SHG signature was directly associated with crosslinking density.75 Thus, in the absence of direct measurement of target engagement (i.e. inhibition of collagen cross-linking activity) the efficacy of AB0023 in inhibiting collagen cross-linking and pathologic tissue stiffness remained uncertain.

 We identified that AB0023 did not significantly inhibit LOXL2 catalytic activity, collagen cross-linking or tissue stiffness within a human disease relevant model of fibrosis. In support of this a recent study identified that AB0023 is only a low potency, partial inhibitor of LOXL2 activity within cell free assays, whilst LOXL2 enzymatic activity in human plasma cannot be inhibited by AB0023.64 The C-terminal domain of LOXL2 contains the active enzyme region which is highly conserved between LOX family members whilst four SRCR domains make up the amino-terminal domain of LOXL2, with the binding epitope of AB0023 mapped to SRCR domain four.27 SRCR domains are found on secreted and cell surface-bound proteins and are proposed to be involved in cell adhesion and signalling.76 A number of studies have identified evidence for SRCR mediated roles of LOXL2 independent of catalytic domain activity including angiogenesis and keratinocyte differentiation.66,67,77

Consistent with previous pre-clinical cancer reports that AB0023 is anti-angiogenic and anti-metastatic we identified a significant reduction in VEGFA and fibronectin within the conditioned media of 3D Spheroids treated with AB0023. It has previously been reported that, independent of the catalytic domain, the SRCR domains of LOXL2 to which AB0023 binds regulate VEGFA transcription and promote VEGFA secretion and angiogenesis.66 Furthermore, it has previously been shown to inhibit VEGF-induced phosphorylation of ERK1/2 in endothelial cells.68 Thus, whilst AB0023 does not significantly inhibit LOXL2 catalytic activity or collagen cross-linking, it is a potent inhibitor of angiogenesis which may account for its effects in animal models. Together these findings suggest the effect of AB0023 is SRCR domain mediated and independent of LOXL2 catalytic inhibition.

 In conclusion, we identified that an *in vitro* 3D spheroid model most closely resembles the transcriptome of human fibroblast foci, further confirming disease relevance through proteomic analyses. Within this model the anti-LOXL2 antibody AB0023 did not inhibit the catalytic activity of LOXL2 or matrix stiffness; in contrast, selective targeting of LOXL2 catalytic activity using a small molecule inhibitor significantly reduced these end-points. These findings inform the failure of simtuzumab to demonstrate anti-fibrotic efficacy in clinical trials of fibrotic diseases where the expectation was to target collagen cross-linking and reduce tissue stiffening.

**Limitations of the study**

This study has a number of limitations. Firstly, whilst we have focussed upon a key feature of human lung fibrogenesis - fibroblast foci - the lung fibrosis microenvironment is complex and includes multiple cell populations. Future investigations will consider the larger microenvironment, and the potential to further leverage spatial ‘omics studies to incorporate additional cell types within the 3D spheroid model so further recapitulating the human lung fibrosis microenvironment *in vitro*. Secondly, we have not provided direct evidence that AB0023 is acting directly via the SRCR domains of LOXL2, with future studies required to further dissect the non-catalytic roles of LOXL2.

# ACKNOWLEDGEMENTS

This project was supported by NC3Rs (NC/V002384/1), the Medical Research Council (MR/S025480/1 & MR/Y002989/1), and the Wellcome Trust (100638/Z/12/Z) and the AAIR Charity. CJB and LW acknowledge the support of the NIHR Southampton Biomedical Research Centre. FC was supported by Medical Research Foundation [MRF-091–0003-RG-CONFO]. The Graphical Abstract and the project design schematic in Figure 2A were created with BioRender.com. We thank Carine Fixmer, Maria Lane, Benjamin Johnson, and the nurses of the Southampton Biomedical Research Unit for their help in the collection of human samples, supported by the Wessex Clinical Research Network and the National Institute of Health Research, UK. We thank Wolfgang Jarolimek at Pharmaxis Ltd. for provision of PXS-S2A and supporting LOXL2 activity assays. We thank Gilead Sciences, Inc. for provision of the AB0023 and Isotype control reagents.

# AUTHOR CONTRIBUTIONS

J.A.B., D.E.D. and M.G.J. conceived and designed the study. J.A.B., E.R.D., C.J.B., L.W., J.JW.R. K.L., E.O., R.A.R., F.C., L.N.S. and J.C. performed all experiments and data analysis. D.J. supported confocal imaging studies. P.M. and Y.W. supported data analysis. A.V.P. supported Bioinformatic analysis. S.J, B.M. and A.A. supported tissue collection. P.S. supported mass spectrometry analysis. M.V. and N.K. supported laser-capture data studies. A.F. supported pathology review and interpretation. All authors read and approved the manuscript.

# DECLARATION OF INTERESTS

M.G.J., D.E.D., and Y.W. acknowledge grants from Boehringer Ingelheim. D.E.D. is co-founder of, shareholder in, and consultant to Synairgen Research Ltd. M.G.J. acknowledges consultancy fees from Skyhawk Therapeutics. J.J.R., K.L., and P.D.M are current employees of Synairgen Research Ltd. L.R. acknowledges grants from Boehringher Ingelheim and consultancy fees from Biogen, Celgene, Boeheringher Ingelheim, Roche, Pliant Therapuetics, BMS, CSL Behring, FibroGen, Veracyte, Chiesi.

# MAIN FIGURE TITLES AND LEGENDS

**Figure 1. The spatial transcriptome of fibroblast foci is enriched for extracellular matrix development and ossification gene expression signatures.**

(A) Principal component analysis (PCA) plot showing variance of the transcriptome (GSE169500) of laser-capture microdissection (LCMD) samples for control alveolar septae, IPF alveolar septae and IPF fibroblast foci (n= 10 control and IPF donors). (B-F). Violin plots showing expression of *ACTA2* (B), *TNC* (C), *COL1A1*(D), *COL5A1*(E) and *SFTPC* (F). Relative expression levels are calculated as Counts per Million reads (CPM). Fibroblastic foci gene expression values are compared with control alveolar septae. (G) Gene Set Variation Analysis (GSVA) of LCMD data, showing top 20 significantly enriched Gene Ontology (GO) terms in IPF fibroblastic foci compared to control alveolar septae. GO terms are ranked by –log10(adjusted P value). (H-I) Violin plots showing GSVA scores for GO terms collagen fibril organisation (H), and bone morphogenesis (I). P values calculated using the EdgeR R package (B-F) and the Limma R package (H-I) comparing fibroblastic foci and IPF alveolar septae to control septae using Benjamini-Hochberg multiple test correction \*P<0.05, \*\*P<0.01, \*\*\*P<0.001, \*\*\*\*P<0.0001.

**Figure 2. The 3D spheroid model most closely reflects the transcriptome of fibroblast foci.**

(A) Schematic representation of the experimental design. Primary parenchymal lung fibroblasts were cultured in standard 2D culture, the Scar-in-a-jar model or the 3D spheroid model in the absence or presence of TGF-β at early and late timepoints (n=4 per condition) and each transcriptome compared through bioinformatic analysis with the transcriptome of fibroblast foci.  (B) Representative phase contrast micrographs of standard 2D culture, scar-in-a-jar and 3D spheroid model. The 3D morphology of spheroids is visualised by confocal microscopy utilising fluorescence of carmine red staining at bandwidths of 500-550 and 690-740nm (green, red false colours respectively). Scale bars are all 200μm (C) Heatmap representing unsupervised hierarchical clustering of highly variable GSVA scores in models and fibroblastic foci (Kruskal-Wallis test, p < 0.01) (D-H) GSVA plots of highly variable gene ontology terms (KW test, p < 0.01) in models compared to fibroblastic foci.

**Figure 3. Clustering of RNAseq data from different fibroblast culture models reveals enrichment for extracellular matrix formation within the 3D spheroid model.**

(A) Heatmap showing hierarchical clustering of RNAseq data of the different fibroblast culture models. Genes shown are all differentially expressed between different models. Box shows upregulated genes within the 3D spheroid model used to identify gene ontology terms in B. (B) G:profiler gene ontology enrichment of genes associated with the 3D spheroid model (+TGF-β) (box in (A). Box denoted GO terms discussed within the manuscript text. (C-G) Violin plots of genes from (A) associated with regulation of the extracellular matrix microenvironment, (C) *COL3A1,* (D) *P4HA3,* (E), *PLOD2*, (F), *HAS1,* (G), *TWIST1*.

**Figure 4.  The 3D spheroid model recapitulates features of the complex extracellular matrix structure identified within fibroblast foci.**

(A) Venn diagram showing the number of unique and common extracellular matrix proteins identified between the fibroblast focus spatial proteome (Herrera *et al.*), and the 3D spheroid model. (B) G:Profiler analysis of 88 ECM proteins common between the fibroblastic focus spatial proteome and the 3D spheroid model proteome. Top 20 most significant Biological Process Gene Ontology terms shown. (C) A comparison of proteomic data derived from the extracellular matrix of IPF tissue (Booth et al.), the fibroblast focus spatial proteome (Herrera et al.) and the 3D spheroid model, showing the top ECM proteins by abundance in IPF ECM and their presence or absence in the other datasets. X indicates proteins that are present and – those which are absent. (D) STRING map showing proteins (File S2C) identified within the 3D spheroid model which have a hazard ratio > 1 in Oldham et al. for increased risk for death or lung transplantation. Each protein has up to 10 medium confidence interaction partners. (E) G:Profiler analysis showing top 10 pathways from proteins identified in (D). (E-F) Representative immunohistochemical staining of IPF lung tissue and 3D spheroids with top left a Masson’s trichrome stain of IPF tissue identifying fibroblast foci by \*, with a serial section bottom left with immunohistochemical staining for Tenascin C (E) or procollagen type 1 (F); on the right-hand side is the corresponding immunohistochemical staining for the 3D spheroid model with a higher magnification inset. Inset scale bars are 50 μm. (G-H) Transmission electron microscopy images of the 3D spheroid model identifying (G) a complex intercalated ECM and (H) the D-banding characteristic of fibrillar collagen. Scale bars are 1 μm (G) and 100 nm (H).

**Figure 5. The anti-LOXL2 antibody AB0023 does not inhibit collagen-cross linking, tissue stiffness nor catalyic amine oxidase activity in a disease relevant model of fibrosis.**

(A) LOXL2 protein levels were assayed in the serum of patients with IPF (n=12) and control subjects (n=13). (B) Expression of *LOXL2* within spatially resolved regions of control and IPF lung tissue. Data from Eyres *et al.*, Cell reports 202230 (C) Representative images of mRNA expression of *LOXL2* (green chromagen) and *PLOD2*  (red chromagen) within a fibroblast focus (\*) of IPF lung tissue and the 3D spheroid model using RNAscope RNA in-situ hybridisation. Scale bars are 20 μm. Arrows indicating cells with co-expression of *LOXL2* and *PLOD2*. (D-I) Lung fibroblasts from IPF patients (n=3 donors across 2 independent experiments) were used in the 3D Spheroid model in the presence of AB0023 or an isotype control antibody at the same concentrations, as well as with PXS-S2A or its vehicle control (0.1% DMSO). (D) Total mature trivalent (PYD+ DPD) collagen cross-links determined by ELISA (n = 3).  (E) Tissue stiffness measured from parallel-plate compression testing determined by Young’s modulus and represented as proportion of control (n = 6). (F) Total collagen content determined by hydroxyproline assay. (G) LOXL2 catalytic amine oxidase activity within the conditioned media was assessed using an activity-based probe (n = 3). (H) VEGFA within cell conditioned media determined by ELISA. (I) Fibronectin within cell conditioned media determined by ELISA. Data are mean +/- SD. \*P<0.05, \*\*P<0.01, \*\*\*P<0.001, \*\*\*\*P<0.0001. Unpaired two-tailed T-test (A) (t = 2.651, degrees of freedom = 23), Wilcoxon test with Benjamini-Hochberg Multiple test correction (B) and ANOVA with Šídák's multiple comparisons test (D-H) were used to evaluate statistical significance (F values: (D) 7.508, (E) 2.862, (F) 0.8966, (G)  33.06, (H) 34.1 (I) 45.03. Degrees of Freedom: (D) 12, (E) 30, (F) 12, (G) 12, (H) 12, (I) 12). Error bars are standard deviation.

**Figure 6. The anti-LOXL2 antibody AB0023 is a potent inhibitor of angiogenesis.**

Endothelial tube formation by human umbilical vein endothelial cells was assessed in the presence of AB0023 or an isotype control antibody at the same concentration (n=10 replicates per condition across 3 independent experiments). (A) Representative images of endothelial tube formation under each condition visualised by calcein staining. Scale bars are 500 μm. (B-D) Quantification of topological parameters of capillary structure by computer-aided image analysis for (B) number of loops, (C) number of branching points, (D) total tube length. Data are means +/- SD. \*P<0.05, \*\*P<0.01, \*\*\*P<0.001, \*\*\*\*P<0.0001. ANOVA with Šídák's multiple comparisons test was used to determine statistical significance. (F statistics: (B) 120.3, (C) 36.31, (D) 74.56, Degrees of Freedom: 36). Error bars are standard deviation.

# STAR+METHODS

**RESOURCE AVAILABILITY**

**Lead contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Professor Mark Jones, mark.jones@soton.ac.uk.

**Materials availability**

This study did not generate new unique reagents.

**Data and code availability**

* RNAseq data from the cell culture studies can be accessed via NCBI Gene Expression Omnibus (GEO) ID GSE255705 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255705). All other data generated during this study are included in the manuscript and supporting files. This paper also analyses existing, publicly available data. The spatial transcriptomic laser capture microdissection dataset of IPF and control lung tissue is available via NCBI Gene Expression Omnibus ID GSE169500. <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE169500> and the digital spatial profiling dataset of IPF and control lung tissue is available within the supplementary dataset of publication Cell Reports. 40:111230. <https://doi.org/10.1016/j.celrep.2022.111230>.
* All original code is available in this paper’s supplemental information in File S3.
* Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

**EXPERIMENTAL MODEL AND SUBJECT DETAILS**

**Clinical Samples**

Studies were approved by the Southampton and South West Hampshire and the Mid and South Buckinghamshire Local Research Ethics Committees (ref 07 /H0607/73, 14/SC/0186 & 348/03/T), and all subjects gave written informed consent. Clinically indicated IPF lung biopsy tissue samples deemed surplus to clinical diagnostic requirements or non-fibrotic parenchymal lung tissue from patients undergoing surgery for early stage lung cancer (macroscopically normal lung sampled remote from a cancer site) were formalin fixed and paraffin embedded or used to establish parenchymal lung fibroblast cultures15. Details of donor characteristics including age, gender, and disease status are provided in Table S1. All IPF samples were from patients subsequently receiving a multidisciplinary diagnosis of IPF according to international consensus guidelines.

**Parenchymal Lung Fibroblast Cultures**

Primary fibroblast cultures were established from parenchymal lung tissue as previously described15. All primary cultures were tested and free of mycoplasma contamination. Sample sizes were selected based on previous comparable studies in the labs in which these studies were performed15,22,37.

2D cell culture37, Scar-in-A-Jar38 and the 3D spheroid model15,22 culture systems used the standard media condition and time for each model system, and a second timepoint (2 weeks) to allow for overlap of culture duration. For this later timepoint, the serum concentration was reduced to 0.5% in the 2D cell culture and Scar-In-A-Jar models to reduce the likelihood of overgrowth of the cell monolayers. The 3D spheroidculture was performed as previously described15, sampling at 2 weeks, as well as the standard 6-week timepoint. For each standard condition and time, cells were cultured in the absence or presence of TGF-β1 (3 ng/mL).

**Primary Human Umbilical Vein Endothelial Cells (HUVEC)**

### HUVECs were purchased from ThermoFisher Scientific (Cat#C0035C) and were human umbilical vein cells from a single, newborn (<14days), female donor. They were cultured on GelTrex basement membrane extract coated plates in human large vessel endothelial cell basal media supplemented with low serum growth supplement, before continuing to the tube forming assay (reported in the *In vitro* human umbilical vein endothelial cell assay section of Method Details). They were tested and free of mycoplasma contamination.

**METHOD DETAILS**

**Spatial Transcriptomic Data Analyses**

We analysed transcriptomic data sets that we have recently established. Briefly, the laser capture microdissection dataset (GSE169500)22 was from Formalin-Fixed Paraffin-Embedded (FFPE) control non-fibrotic lung tissue (alveolar septae, [n = 10]) and usual interstitial pneumonia/idiopathic pulmonary fibrosis FFPE lung tissue (fibroblast foci, [n = 10] and adjacent non-affected alveolar septae, [n = 10]). Fibroblast foci were identified using the ARCTURUS® Paradise® PLUS FFPE LCM Staining Kit (ThermoFisher Scientific) by the staining pattern of the myxoid extracellular matrix, whilst selection of alveolar septae excluded visible airways and blood vessels. Total RNA was isolated, cDNA libraries were prepared using Ion Ampli‐Seq‐transcriptome human gene expression kit (Life Technologies, Paisley, UK) and sequenced using Ion Torrent Proton Sequencer. A two-stage mapping strategy was used to map the reads to UCSC hg19 human genome. Raw counts data were then normalised to counts per million mapped reads using edgeR.

The digital spatial profiling dataset36 for LOXL2 spatial expression we previously generated from Nanostring GeoMx CTA profiling of 1813 unique genes within 60 regions of interest (control alveolar septae, IPF distant alveolar septae, IPF adjacent alveolar septae, IPF fibroblastic foci, IPF immune infiltrates, IPF blood vessels, and control blood vessels). Full data are available within the published supplemental files.36

**Carmine red staining of fixed spheroids**

To assess the 3D morphology of spheroids, the multispectral autofluorescence of carmine red and confocal microscopy were used. Spheroids were fixed in PFA and stored in PBS before post-fixing in 48% ethanol:2% glacial acetic acid: 10% formaldehyde and staining in Langeron’s carmine. Following differentiation in acid alcohol, stained spheroids were optically-cleared by dehydration through a graded methanol series (50%, 70%, 80%, 95%, 100%, 2 changes of each), then 2:1 dichloromethane (DCM):methanol, followed by 2 changes of DCM and 3 changes of dibenzylether (DBE). Samples were imaged in DBE in glass bottom Ibidi chamberslides on a Leica TCS-SP8 confocal microscope on an inverted dmi8 microscope stand using an HC PL APO CS2 20x/0.75 IMM objective with glycerol:water (8:2) as immersion fluid. Multichannel imaging was undertaken using system-optimised Z spacing, excitation at 488 and 561nm and capturing carmine autofluorescence emission at bandwidths of 500-550 and 690-740nm (green, red false colours respectively).

**RNAseq and Bioinformatic Analyses**

Cells were harvested at specified timepoints for each model system and RNA isolated using the RNeasy Mini kits (Qiagen, Manchester, UK) according to the manufacturer’s instructions. For the 3D spheroid model, RLT buffer also contained Proteinase K (Sigma, Poole, UK) to aid digestion of the ECM and facilitate cell lysis.

RNAseq was performed by Novogene (UK) using an Illumina Novaseq 6000 sequencer. cDNA libraries were mRNA enriched using polyA enrichment, and ~150bp paired-end reads were quantified from these cDNA libraries. Raw fastq files were pseudoaligned to human reference transcriptome hg38, derived from human reference genome GRCh38, using RefSeq’s transcripts to construct an index file. Pseudoalignments were completed using Kallisto running in paired end mode, to calculate raw counts.

Raw, transcript-level counts data were imported into R using the tximport package or downloaded from the Gene Expression Omnibus.78 Differential expression analysis was performed using edgeR79 with multiple test correction performed using the Benjamini-Hochberg methodology. Counts per million reads were calculated using edgeR for models and laser capture microdissection data. LCMD and models data were combined before Gene Set Variation Analysis was performed using the gsva R package, with differential scores calculated between all groups using a Kruskal Wallis test with B-H multiple test correction. with differential regulation of gene sets assessed using the Limma R package.80,81 Graphs were produced using ggplot2.

**Proteomic Analysis**

Proteomic analysis was performed on 3D spheroids and their secreted proteins; for secretome studies, spheroids were washed and cultured in serum free media for 24 hours prior to collection of the conditioned medium for analysis.

Spheroids were pooled in pairs to yield approximately 100 mg protein per sample and were lysed in 0.1% sodium dodecyl sulfate in an ultrasonic bath followed by a sonication probe.

Protein lysates were precipitated by methanol/chloroform extraction then reduced for 1 hour with 1 mM dithiothreitol followed by alkylation for 45 minutes with 5.5 mM iodoacetamide in the dark at room temperature. Samples were digested with endoproteinase Lys-C for 4 hours then 2 mg trypsin overnight at room temperature. Enolase and ClpB internal reference standards were spiked at 300 fmol. Peptides were then fractionated by OFFgel electrophoresis into 12 peptide fractions according to manufacturer's instructions. Each fraction was purified using a C18 Empore 96-well solid phase extraction plate, before evaporation to dryness and resuspension in loading buffer (3% acetonitrile + 0.1% formic acid) for mass spectrometry analysis. Each experiment was performed in triplicate. For the secretome, media from five individual culture wells per cell donor were combined. Protein was bound to StrataClean resin beads (Agilent) by incubation for 1hr at 2-8oC, followed by sequential reduction using DTT, alkylation using iodoacetamide, and digestion with sequencing grade trypsin. After elution from the beads, samples were subjected to SPE clean-up on C18 columns and sample concentration.

Fractions were analysed by UPLC-HDMSE. Half of each fraction was injected and peptides were separated by liquid chromatography using a NanoAcquity UPLC system (Waters, Elstree, UK) with a C18 reverse-phase column at a flow rate of 300 nL/minute over a 3-50% 80% acetonitrile/dH2O + 0.1% formic acid gradient of 90 minutes. Peptide ions were sprayed into a Waters Synapt G2-S system operating in positive ion mode, with ion mobility enabled prior to fragmentation. Data were collected in MSE mode of acquisition, alternating between low energy (5V) and high energy (15V - 45V ramp) scans. Glu-fibrinopeptide (m/z = 785.8426, 100 fmol/ml) was used as LockMass and was sampled every 60 seconds for calibration.

Raw data files were processed using Protein Lynx Global Server (PLGS) version 3.0 (Waters, Elstree, UK). Data were searched against the human UniProt database (downloaded 29/11/2013) using an Ion Accounting algorithm in PLGS 3.0.2.

Proteomic data were processed in R, with proteins identified in at least one sample in the fibroblastic foci proteomic data59 and the 3D model proteomic data included. Extracellular matrix proteins including core matrix proteins, secreted proteins and basement membrane proteins were acquired from Naba *et al*.82 Basement membrane proteins were excluded from both the fibroblastic focus and 3D spheroid model proteomes, before cross-referencing protein names to identify common and different ECM proteins between the two datasets. IPF extracellular proteomic data were derived from Booth *et al.,*83and the most abundant extracellular matrix proteins present in decellularized IPF tissue excluding basement membrane proteins, ordered by their abundance in the Booth dataset were cross-referenced with the 3D spheroid model proteome and the fibroblastic focus proteome.

3D proteomic data was also cross-referenced with proteins identified as having a hazard ration > 1 in a study of proteomic biomarkers of outcome in IPF.58 Protein lists were mapped along with up to 50 primary and secondary interaction partners using STRING (v11)84 to demonstrate their interaction network (Fig S2).

**Luminex Analysis**

Supernatants derived from each model system were taken and analyte concentration in the supernatant was quantified against a standard curve using a Human Luminex Discovery Assay Kit (R&D systems LXSAHM), analysed on the Magpix Luminex platform. Luminex data were normalised to total RNA and media volume to allow comparison across different culture models.

**Immunohistochemistry**

Sections (4 μm) of lung tissue or 3D spheroid model (fixed in 4% paraformaldehyde and paraffin embedded) were processed and stained as previously described.15,37,85 Briefly, the tissue sections were de-waxed, rehydrated and incubated with 3% hydrogen peroxide in methanol for 10 min to block endogenous peroxidase activity. Sections were then blocked with normal goat serum and incubated at room temperature with a primary antibody against tenascin C (1:500, Abcam ab108930) or procollagen type I (1:100, Abcam ab64409); after washing, bound antibody was detected using a biotinylated secondary antibody (1:500, Vector Laboratories Ltd., UK) followed by streptavidin-conjugated horse-radish peroxidase and visualisation using DAB. Sections were counter-staining with Gill’s Haematoxylin. For co-localisation studies, adjacent serial sections were stained using modified Movat’s Pentachrome Stain86. Images were acquired using an Olympus Dotslide Scanner VS110.

**Transmission electron microscopy (TEM)**

TEM was performed on 3D spheroids as previously described.15 Briefly, spheroids were fixed in 3% glutaraldehyde in 0.1 M cacodylate buffer at pH 7.4 for electron microscopy. Samples were then post-fixed sequentially in osmium/ferrocyanide fixative, thiocarbohydrazide solution, osmium tetroxide, uranyl acetate and Walton’s lead aspartate solution before dehydration in graded ethanol and acetonitrile. Samples were embedded in Spurr resin and 100 nm ultra-thin sections visualised using an FEI Tecnai 12 transmission electron microscope (FEI Company, Hillsboro, OR, USA).

**LOXL2 Serum Assay**

LOXL2 concentration was measured in serum as previously reported.64 Briefly, a sandwich using two commercially available antibodies and a high sensitivity detection method were used to determine LOXL2 concentrations. Calibrations curves were derived from testing human recombinant LOXL2.

**RNA in-situ hybridisation**

Simultaneous in situ detection of the LOXL2 and PLOD2 mRNA on formalin-fixed paraffin-embedded tissue sections was performed using duplex RNAscope technology (Advanced Cell Diagnostics, Biotechne, Abingdon, UK) as previously reported.22 Briefly, LOXL2 was detected by C1-probe (Probe-Hs-LOXL2-C1, 311341) and PLOD2 was detected by C2-probe (Probe-Hs-PLOD2-C2, 547761-C2). 5 μm sections were baked at 60 °C, deparaffinised in xylene, followed by rehydration in an ethanol series. Target retrieval, hybridisation with target probes, amplification, and chromogenic detection were performed according to the manufacturer’s recommendations (RNAscope 2.5 Duplex Detection protocol for FFPE tissues). Sections were counterstained with Gill’s Hematoxylin, and mounted with Vectamount permanent mounting medium prior to imaging. Assays were performed with duplex positive (PPIB and POLR2A) and negative controls. Images were acquired using an Olympus Dotslide Scanner VS110 (Olympus UK, Southend-on-Sea, UK).

**Evaluation of AB0023 in the 3D Spheroid Model**

For studies of AB0023 in the 3D spheroid model, all experiments were performed in the presence of TGF-β1 (3 ng/mL), the condition that most closely recapitulated a fibroblastic focus. AB0023 or an isotype control IgG antibody were tested at 2.5μg/ml and 25μg/ml and were present in the medium for the duration of the culture and were replenished every 3 days. As a positive control, we also included PXS-S2A at 100nM, a concentration which we have shown to inhibit LOXL215 and its vehicle control (0.1%DMSO). AB0023 and the isotype control IgG antibody were kindly supplied by Gilead, while PXS-S2A was from Pharmaxis. After 6 weeks of culture, the cell-free medium was harvested for measurement of LOXL2 activity and the spheroids processed for analysis of tissue stiffness, total protein, collagen and pyridinoline cross-links, all as detailed below.

**LOXL2 Activity Assay**

LOXL2 catalytic amine oxidase activity within the cell conditioned media of 3D spheroids was measured as previously reported using the PXS‐5878/Simoa® platform.64 Briefly, an activity‐based probe, PXS‐5878 which potently and irreversibly binds to unoccupied lysyl oxidase active sites was used in combination with a LOXL2 capturing antibody.

**Protein, hydroxyproline and collagen cross-link analysis**

Analysis was performed as previously described.15,22 Briefly, samples were thawed and reduced with KBH4 before acid hydrolysis in 6M HCl at 102°C for 18 hr. Cooled hydrolysed samples were evaporated to dryness under vacuum and then resuspended in 200 μL HPLC-grade H2O. Total protein was quantified in the hydrolysed samples using a genipin-based amino acid assay (QuickZyme Biosciences, Leiden, The Netherlands), using standard hydrolysed bovine serum albumin as standard. Total collagen content was estimated using colorimetric assay of hydroxyproline (Hyp) based on the reaction of oxidized hydroxyproline with 4-(Dimethylamino) benzaldehyde, as per manufacturer’s instruction (Sigma-Aldrich, Poole, UK). The molar content of collagen was estimated from hydroxyproline using a conversion factor of 300 hydroxyprolines per triple helix, and mass of collagen was estimated using a molecular weight of 300 kDa per triple helix. Total mature pyridinium cross-links (PYD +DPD) were determined using enzyme-linked immunosorbent assay (ELISA; Quidel Corporation, San Diego, USA) according to manufacturer’s instructions. Quantitation of the collagen cross-links and total collagen was achieved by comparing to a standard curve. Sample values were interpolated using GraphPad Prism seven software.

**Parallel plate compression testing**

Analysis was performed as previously described.15 Briefly, to determine the stiffness characteristics (Young’s modulus, E) of the 3D in vitro model of fibrosis, cultures were subjected to parallel plate compression testing using a CellScale MicroSquisher fitted with a round tungsten cantilever (thickness 406.4 nm) and accompanying SquisherJoy V5.23 software (CellScale, Ontario, Canada). Analysis of stress vs strain relationships was carried out using the compression phase of the fifth cycle from where sample stiffness can be inferred. Force and displacement data were transformed to engineering stress versus engineering strain plots using the horizontal cross-sectional diameter of the sample immediately before the start of each test. Young’s modulus (E), a measure of stiffness, was calculated using a modified Hertzian half-space contact mechanics model for elastic spheres as previously described.15,22

### **Enzyme-linked Immuno-sorbent assay**

VEGFA and Fibronectin concentrations were assayed in conditioned media from 3D spheroid models using Human VEGF DuoSet ELISA and Human Fibronectin DuoSet ELISA kits (RnD systems).

### ***In vitro* human umbilical vein endothelial cell assay**

Tube formation was performed using human umbilical vein endothelial cells (HUVECs) (supplied by ThermoFisher Scientific) cultured on Geltrex basement membrane extract (also from ThermoFisher Scientific) following the manufacturer’s protocol. Briefly, HUVECs were loaded with Calcein AM (Invitrogen) for 30 mins before being seeded onto Geltrex-coated 48-well tissue culture plates. Tube formation was induced by addition 2% FBS and bFGF (3 ng/mL) for 16-20 h. AB0023 or isotype control IgG were added at 2.5 or 25µg/mL. Suramin (30 µM) was included as a positive inhibitor control. Immunofluorescent images of tubes were taken after 24 h and the extent of tube formation assessed by the online image analysis “WimTube tool” (Wimasis, Munich, Germany) to quantify the number of loops, branches and total tube length.

**Quantitative real time PCR (qPCR)**

QPCR was performed using TaqMan Fast Advanced Master mix (Thermo Fisher) in a Bio-Rad CFX Opus 96 thermocycler.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

Statistical analyses were performed in R version 4.2.2, or GraphPad Prism v9.4.1 (GraphPad Software Inc, San Diego, CA) unless otherwise indicated. Details of R analysis can be found in supplemental code (File S3). No data were excluded from the studies and for all experiments, all attempts at replication were successful. For each experiment, sample size reflects the number of independent biological replicates and is provided in the figure legend. Normality of distribution was assessed using the D’Agostino-Pearson normality test. Statistical analyses of single comparisons of two groups utilised Student’s t-test. Graphs show the mean and error bars represent standard deviation. For multiple comparisons, one-way analysis of variance (ANOVA) with Šídák's multiple comparisons test or Kruskal-Wallis analysis with Dunn’s multiple comparison test were used for parametric and non-parametric data, respectively. Results were considered significant if p < 0.05, where \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001. Statistical details can also be found in the figure legends.

# SUPPLEMENTAL FILE LEGENDS

**Supplemental Information**

**Document S1. Figures S1-S4,** related to Figures 3, 5 and 6 and Table S1, related to Figures 1-5.

**File S1: Gene Set Variation Analysis Results,** related to Figure 2. Analysis of the transcriptome (GSE169500) of laser-capture microdissection samples for control alveolar septae, IPF alveolar septae and IPF fibroblast foci (n = 10 control and IPF donors) and fibroblast culture models and IPF fibroblastic foci LCMD data (n = 4 Biological replicates for culture models). **A** Gene Ontology (GO) terms ordered by adjusted P values multiplied by the sign of logFC values, comparing fibroblastic focus samples with control alveolar septae samples. P values calculated on GSVA results using the Limma R package. **B** GO GSVA scores. **C.** Gene Ontology (GO) terms ordered by adjusted P values from Kruskal-Wallis test comparing GO GSVA scores for different fibroblast culture models and IPF fibroblastic foci **D.** GO GSVA scores for combined fibroblast culture models and IPF fibroblastic foci dataset.

**File S2: 3D spheroid model full proteomic data,** related to Figure 4. **A** Common and distinct extracellular matrix proteins in the 3D spheroid model when compared to the fibroblast focus proteome generated by Herrera *et al.,* JCI Insight, 2022.33. The extracellular matrix reference was obtained from Naba *et al.,* Matrix Biology (2016)55 and excludes basement membrane proteins. **B** Combined Proteome and secretome data from IPF-derived 3D spheroids of all proteins detected (n = 3 donors for proteome, n = 4 donors for secretome). **C** Proteins which have a hazard ratio > 1 for survival in lung fibrosis (taken from Oldham et al. 202358) which are also produced by 3D spheroid model.

**File S3: R code used for this analysis,** related to Figures 1-5.

# REFERENCES

1. Richeldi, L., Collard, H.R., and Jones, M.G. (2017). Idiopathic pulmonary fibrosis. The Lancet *389*, 1941–1952. https://doi.org/10.1016/S0140-6736(17)30866-8.

2. Wipff, P.-J., Rifkin, D.B., Meister, J.-J., and Hinz, B. (2007). Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol *179*, 1311–1323. 10.1083/jcb.200704042.

3. Liu, F., Mih, J.D., Shea, B.S., Kho, A.T., Sharif, A.S., Tager, A.M., and Tschumperlin, D.J. (2010). Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biol *190*, 693–706. 10.1083/jcb.201004082.

4. Zhou, Y., Huang, X., Hecker, L., Kurundkar, D., Kurundkar, A., Liu, H., Jin, T.-H., Desai, L., Bernard, K., and Thannickal, V.J. (2013). Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest *123*, 1096–1108. 10.1172/JCI66700.

5. Parker, M.W., Rossi, D., Peterson, M., Smith, K., Sikström, K., White, E.S., Connett, J.E., Henke, C.A., Larsson, O., and Bitterman, P.B. (2014). Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest *124*, 1622–1635. 10.1172/JCI71386.

6. Tschumperlin, D.J., Ligresti, G., Hilscher, M.B., and Shah, V.H. Mechanosensing and fibrosis. J Clin Invest *128*, 74–84. 10.1172/JCI93561.

7. Herrera, J., Henke, C.A., and Bitterman, P.B. Extracellular matrix as a driver of progressive fibrosis. J Clin Invest *128*, 45–53. 10.1172/JCI93557.

8. Jones, M.G., Fabre, A., Schneider, P., Cinetto, F., Sgalla, G., Mavrogordato, M., Jogai, S., Alzetani, A., Marshall, B.G., O’Reilly, K.M.A., et al. Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis. JCI Insight *1*. 10.1172/jci.insight.86375.

9. Fiore, V.F., Wong, S.S., Tran, C., Tan, C., Xu, W., Sulchek, T., White, E.S., Hagood, J.S., and Barker, T.H. αvβ3 Integrin drives fibroblast contraction and strain stiffening of soft provisional matrix during progressive fibrosis. JCI Insight *3*, e97597. 10.1172/jci.insight.97597.

10. Herrera, J., Forster, C., Pengo, T., Montero, A., Swift, J., Schwartz, M.A., Henke, C.A., and Bitterman, P.B. (2019). Registration of the extracellular matrix components constituting the fibroblastic focus in idiopathic pulmonary fibrosis. JCI Insight *4*. 10.1172/jci.insight.125185.

11. King, T.E., Schwarz, M.I., Brown, K., Tooze, J.A., Colby, T.V., Waldron, J.A., Flint, A., Thurlbeck, W., and Cherniack, R.M. (2001). Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med *164*, 1025–1032. 10.1164/ajrccm.164.6.2001056.

12. Flaherty, K.R., Colby, T.V., Travis, W.D., Toews, G.B., Mumford, J., Murray, S., Thannickal, V.J., Kazerooni, E.A., Gross, B.H., Lynch, J.P., et al. (2003). Fibroblastic Foci in Usual Interstitial Pneumonia. Am J Respir Crit Care Med *167*, 1410–1415. 10.1164/rccm.200204-373OC.

13. Harada, T., Watanabe, K., Nabeshima, K., Hamasaki, M., and Iwasaki, H. (2013). Prognostic significance of fibroblastic foci in usual interstitial pneumonia and non-specific interstitial pneumonia. Respirology *18*, 278–283. 10.1111/j.1440-1843.2012.02272.x.

14. Senior, R.M., Bielefeld, D.R., and Abensohn, M.K. (1975). The Effects of Proteolytic Enzymes on the Tensile Strength of Human Lung. Am Rev Respir Dis *111*, 184–188. 10.1164/arrd.1975.111.2.184.

15. Jones, M.G., Andriotis, O.G., Roberts, J.J., Lunn, K., Tear, V.J., Cao, L., Ask, K., Smart, D.E., Bonfanti, A., Johnson, P., et al. (2018). Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis. eLife *7*, e36354. 10.7554/eLife.36354.

16. Shoulders, M.D., and Raines, R.T. (2009). COLLAGEN STRUCTURE AND STABILITY. Annu Rev Biochem *78*, 929–958. 10.1146/annurev.biochem.77.032207.120833.

17. Kadler, K.E., Holmes, D.F., Trotter, J.A., and Chapman, J.A. (1996). Collagen fibril formation. Biochem J *316*, 1–11.

18. Yamauchi, M., and Sricholpech, M. (2012). Lysine post-translational modifications of collagen. Essays In Biochemistry *52*, 113–133. 10.1042/bse0520113.

19. Trackman, P.C. (2016). Lysyl Oxidase Isoforms and Potential Therapeutic Opportunities for Fibrosis and Cancer. Expert Opinion on Therapeutic Targets *20*, 935–945. 10.1517/14728222.2016.1151003.

20. Barry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H.M., Oyasu, M., Mikels, A., Vaysberg, M., Ghermazien, H., Wai, C., et al. (2010). Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment. Nature Medicine *16*, 1009–1017. 10.1038/nm.2208.

21. Yang, J., Savvatis, K., Kang, J.S., Fan, P., Zhong, H., Schwartz, K., Barry, V., Mikels-Vigdal, A., Karpinski, S., Kornyeyev, D., et al. (2016). Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nat Commun *7*, 13710. 10.1038/ncomms13710.

22. Brereton, C.J., Yao, L., Davies, E.R., Zhou, Y., Vukmirovic, M., Bell, J.A., Wang, S., Ridley, R.A., Dean, L.S., Andriotis, O.G., et al. (2022). Pseudohypoxic HIF pathway activation dysregulates collagen structure-function in human lung fibrosis. eLife *11*, e69348. 10.7554/eLife.69348.

23. Chien, J.W., Richards, T.J., Gibson, K.F., Zhang, Y., Lindell, K.O., Shao, L., Lyman, S.K., Adamkewicz, J.I., Smith, V., Kaminski, N., et al. (2014). Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. European Respiratory Journal *43*, 1430–1438. 10.1183/09031936.00141013.

24. Harrison, S.A., Abdelmalek, M.F., Caldwell, S., Shiffman, M.L., Diehl, A.M., Ghalib, R., Lawitz, E.J., Rockey, D.C., Schall, R.A., Jia, C., et al. (2018). Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. Gastroenterology *155*, 1140–1153. 10.1053/j.gastro.2018.07.006.

25. Muir, A.J., Levy, C., Janssen, H.L.A., Montano‐Loza, A.J., Shiffman, M.L., Caldwell, S., Luketic, V., Ding, D., Jia, C., McColgan, B.J., et al. (2019). Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology *69*, 684. 10.1002/hep.30237.

26. Raghu, G., Brown, K.K., Collard, H.R., Cottin, V., Gibson, K.F., Kaner, R.J., Lederer, D.J., Martinez, F.J., Noble, P.W., Song, J.W., et al. (2017). Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respir Med *5*, 22–32. 10.1016/S2213-2600(16)30421-0.

27. Rodriguez, H.M., Vaysberg, M., Mikels, A., McCauley, S., Velayo, A.C., Garcia, C., and Smith, V. (2010). Modulation of Lysyl Oxidase-like 2 Enzymatic Activity by an Allosteric Antibody Inhibitor. Journal of Biological Chemistry *285*, 20964–20974. 10.1074/jbc.M109.094136.

28. Jenkins, R.G., Moore, B.B., Chambers, R.C., Eickelberg, O., Königshoff, M., Kolb, M., Laurent, G.J., Nanthakumar, C.B., Olman, M.A., Pardo, A., et al. (2017). An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis. Am J Respir Cell Mol Biol *56*, 667–679. 10.1165/rcmb.2017-0096ST.

29. Tashiro, J., Rubio, G.A., Limper, A.H., Williams, K., Elliot, S.J., Ninou, I., Aidinis, V., Tzouvelekis, A., and Glassberg, M.K. (2017). Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis. Front Med (Lausanne) *4*. 10.3389/fmed.2017.00118.

30. Jones, M.G., Fletcher, S., and Richeldi, L. (2013). Idiopathic Pulmonary Fibrosis: Recent Trials and Current Drug Therapy. RES *86*, 353–363. 10.1159/000356958.

31. Decaris, M.L., Gatmaitan, M., FlorCruz, S., Luo, F., Li, K., Holmes, W.E., Hellerstein, M.K., Turner, S.M., and Emson, C.L. (2014). Proteomic Analysis of Altered Extracellular Matrix Turnover in Bleomycin-induced Pulmonary Fibrosis. Molecular & Cellular Proteomics *13*, 1741–1752. 10.1074/mcp.M113.037267.

32. Loewa, A., Feng, J.J., and Hedtrich, S. (2023). Human disease models in drug development. Nat Rev Bioeng *1*, 545–559. 10.1038/s44222-023-00063-3.

33. Madhusoodanan, J. (2019). Matrix mimics shape cell studies. Nature *566*, 563–565. 10.1038/d41586-019-00681-1.

34. Sacchi, M., Bansal, R., and Rouwkema, J. (2020). Bioengineered 3D Models to Recapitulate Tissue Fibrosis. Trends in Biotechnology *38*, 623–636. 10.1016/j.tibtech.2019.12.010.

35. Marx, V. (2021). Method of the Year: spatially resolved transcriptomics. Nat Methods *18*, 9–14. 10.1038/s41592-020-01033-y.

36. Eyres, M., Bell, J.A., Davies, E.R., Fabre, A., Alzetani, A., Jogai, S., Marshall, B.G., Johnston, D.A., Xu, Z., Fletcher, S.V., et al. (2022). Spatially resolved deconvolution of the fibrotic niche in lung fibrosis. Cell Reports *40*. 10.1016/j.celrep.2022.111230.

37. Conforti, F., Ridley, R., Brereton, C., Alzetani, A., Johnson, B., Marshall, B.G., Fletcher, S.V., Ottensmeier, C.H., Richeldi, L., Skipp, P., et al. (2020). Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis. Cell Death Discov. *6*, 1–11. 10.1038/s41420-020-0289-9.

38. Chen, C., Peng, Y., Wang, Z., Fish, P., Kaar, J., Koepsel, R., Russell, A., Lareu, R., and Raghunath, M. (2009). The Scar-in-a-Jar: studying potential antifibrotic compounds from the epigenetic to extracellular level in a single well. Br J Pharmacol *158*, 1196–1209. 10.1111/j.1476-5381.2009.00387.x.

39. Yeo, S.-Y., Lee, K.-W., Shin, D., An, S., Cho, K.-H., and Kim, S.-H. (2018). A positive feedback loop bi-stably activates fibroblasts. Nat Commun *9*, 3016. 10.1038/s41467-018-05274-6.

40. Luo, Y., Xu, W., Chen, H., Warburton, D., Dong, R., Qian, B., Selman, M., Gauldie, J., Kolb, M., and Shi, W. (2015). A novel profibrotic mechanism mediated by TGF-β-stimulated collagen prolyl hydroxylase expression in fibrotic lung mesenchymal cells. J Pathol *236*, 384–394. 10.1002/path.4530.

41. Valenzi, E., Bahudhanapati, H., Tan, J., Tabib, T., Sullivan, D.I., Nouraie, M., Sembrat, J., Fan, L., Chen, K., Liu, S., et al. (2023). Single-Nucleus Chromatin Accessibility Identifies a Critical Role for TWIST1 in IPF Myofibroblast Activity. European Respiratory Journal. 10.1183/13993003.00474-2022.

42. Radwanska, A., Cottage, C.T., Piras, A., Overed-Sayer, C., Sihlbom, C., Budida, R., Wrench, C., Connor, J., Monkley, S., Hazon, P., et al. (2022). Increased expression and accumulation of GDF15 in IPF extracellular matrix contribute to fibrosis. JCI Insight *7*. 10.1172/jci.insight.153058.

43. Almuntashiri, S., Alhumaid, A., Zhu, Y., Han, Y., Dutta, S., Khilji, O., Zhang, D., and Wang, X. (2023). TIMP-1 and its potential diagnostic and prognostic value in pulmonary diseases. Chinese Medical Journal Pulmonary and Critical Care Medicine *1*, 67–76. 10.1016/j.pccm.2023.05.002.

44. Estany, S., Vicens-Zygmunt, V., Llatjós, R., Montes, A., Penín, R., Escobar, I., Xaubet, A., Santos, S., Manresa, F., Dorca, J., et al. (2014). Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFβ1. BMC Pulm Med *14*, 120. 10.1186/1471-2466-14-120.

45. Yoshihara, T., Nanri, Y., Nunomura, S., Yamaguchi, Y., Feghali-Bostwick, C., Ajito, K., Murakami, S., Mawatari, M., and Izuhara, K. (2020). Periostin plays a critical role in the cell cycle in lung fibroblasts. Respiratory Research *21*, 38. 10.1186/s12931-020-1299-0.

46. Zhu, X., Ji, J., and Han, X. (2024). Osteopontin: an essential regulatory protein in idiopathic pulmonary fibrosis. J Mol Histol *55*, 1–13. 10.1007/s10735-023-10169-y.

47. Atamas, S.P. (2017). Vascular Endothelial Growth Factor in Idiopathic Pulmonary Fibrosis. An Imbalancing Act. Am J Respir Crit Care Med *196*, 409–411. 10.1164/rccm.201703-0605ED.

48. Suga, M., Iyonaga, K., Ichiyasu, H., Saita, N., Yamasaki, H., and Ando, M. (1999). Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases. Eur Respir J *14*, 376–382. 10.1034/j.1399-3003.1999.14b23.x.

49. Liu, S., Liu, C., Wang, Q., Liu, S., and Min, J. (2023). CC Chemokines in Idiopathic Pulmonary Fibrosis: Pathogenic Role and Therapeutic Potential. Biomolecules *13*, 333. 10.3390/biom13020333.

50. Russo, R.C., Alessandri, A.L., Garcia, C.C., Cordeiro, B.F., Pinho, V., Cassali, G.D., Proudfoot, A.E.I., and Teixeira, M.M. (2011). Therapeutic Effects of Evasin-1, a Chemokine Binding Protein, in Bleomycin-Induced Pulmonary Fibrosis. Am J Respir Cell Mol Biol *45*, 72–80. 10.1165/rcmb.2009-0406OC.

51. Keane, M.P., Belperio, J.A., Moore, T.A., Moore, B.B., Arenberg, D.A., Smith, R.E., Burdick, M.D., Kunkel, S.L., and Strieter, R.M. (1999). Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol *162*, 5511–5518.

52. Strieter, R.M., Gomperts, B.N., and Keane, M.P. (2007). The role of CXC chemokines in pulmonary fibrosis. J Clin Invest *117*, 549–556. 10.1172/JCI30562.

53. Sung, E.-A., Park, M.H., Henegariu, O., Sime, P.J., and Chae, W.-J. (2023). Dickkopf1 Promotes Pulmonary Fibrosis upon Bleomycin-Induced Lung Injury. The American Journal of Pathology *193*, 1130–1142. 10.1016/j.ajpath.2023.05.009.

54. Yang, P., Luo, Q., Wang, X., Fang, Q., Fu, Z., Li, J., Lai, Y., Chen, X., Xu, X., Peng, X., et al. Comprehensive Analysis of Fibroblast Activation Protein Expression in Interstitial Lung Diseases. Am J Respir Crit Care Med *207*, 160–172. 10.1164/rccm.202110-2414OC.

55. Matute-Bello, G., Wurfel, M.M., Lee, J.S., Park, D.R., Frevert, C.W., Madtes, D.K., Shapiro, S.D., and Martin, T.R. (2007). Essential Role of MMP-12 in Fas-Induced Lung Fibrosis. Am J Respir Cell Mol Biol *37*, 210–221. 10.1165/rcmb.2006-0471OC.

56. Dancer, R.C.A., Wood, A.M., and Thickett, D.R. (2011). Metalloproteinases in idiopathic pulmonary fibrosis. European Respiratory Journal *38*, 1461–1467. 10.1183/09031936.00024711.

57. Senoo, T., Hattori, N., Tanimoto, T., Furonaka, M., Ishikawa, N., Fujitaka, K., Haruta, Y., Murai, H., Yokoyama, A., and Kohno, N. (2010). Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax *65*, 334–340. 10.1136/thx.2009.119974.

58. Oldham, J.M., Huang, Y., Bose, S., Ma, S.-F., Kim, J.S., Schwab, A., Ting, C., Mou, K., Lee, C.T., Adegunsoye, A., et al. (2023). Proteomic Biomarkers of Survival in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 10.1164/rccm.202301-0117OC.

59. Herrera, J.A., Dingle, L., Montero, M.A., Venkateswaran, R.V., Blaikley, J.F., Lawless, C., and Schwartz, M.A. (2022). The UIP/IPF fibroblastic focus is a collagen biosynthesis factory embedded in a distinct extracellular matrix. JCI Insight *7*, e156115. 10.1172/jci.insight.156115.

60. Naik, P.K., Bozyk, P.D., Bentley, J.K., Popova, A.P., Birch, C.M., Wilke, C.A., Fry, C.D., White, E.S., Sisson, T.H., Tayob, N., et al. (2012). Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol *303*, L1046–L1056. 10.1152/ajplung.00139.2012.

61. Vuga, L.J., Milosevic, J., Pandit, K., Ben-Yehudah, A., Chu, Y., Richards, T., Sciurba, J., Myerburg, M., Zhang, Y., Parwani, A.V., et al. (2013). Cartilage Oligomeric Matrix Protein in Idiopathic Pulmonary Fibrosis. PLoS One *8*, e83120. 10.1371/journal.pone.0083120.

62. Aumiller, V., Strobel, B., Romeike, M., Schuler, M., Stierstorfer, B.E., and Kreuz, S. (2017). Comparative analysis of lysyl oxidase (like) family members in pulmonary fibrosis. Sci Rep *7*, 149. 10.1038/s41598-017-00270-0.

63. Chang, J., Lucas, M.C., Leonte, L.E., Garcia-Montolio, M., Singh, L.B., Findlay, A.D., Deodhar, M., Foot, J.S., Jarolimek, W., Timpson, P., et al. (2017). Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer. Oncotarget *8*, 26066–26078. 10.18632/oncotarget.15257.

64. Findlay, A., Turner, C., Schilter, H., Deodhar, M., Zhou, W., Perryman, L., Foot, J., Zahoor, A., Yao, Y., Hamilton, R., et al. (2021). An activity-based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti-fibrotic therapeutic strategies. Clin Transl Med *11*, e572. 10.1002/ctm2.572.

65. Wu, S., Zheng, Q., Xing, X., Dong, Y., Wang, Y., You, Y., Chen, R., Hu, C., Chen, J., Gao, D., et al. (2018). Matrix stiffness-upregulated LOXL2 promotes fibronectin production, MMP9 and CXCL12 expression and BMDCs recruitment to assist pre-metastatic niche formation. Journal of Experimental & Clinical Cancer Research *37*, 99. 10.1186/s13046-018-0761-z.

66. Peng, T., Deng, X., Tian, F., Li, Z., Jiang, P., Zhao, X., Chen, G., Chen, Y., Zheng, P., Li, D., et al. (2019). The interaction of LOXL2 with GATA6 induces VEGFA expression and angiogenesis in cholangiocarcinoma. Int J Oncol *55*, 657–670. 10.3892/ijo.2019.4837.

67. Umana-Diaz, C., Pichol-Thievend, C., Marchand, M.F., Atlas, Y., Salza, R., Malbouyres, M., Barret, A., Teillon, J., Ardidie-Robouant, C., Ruggiero, F., et al. (2020). Scavenger Receptor Cysteine-Rich domains of Lysyl Oxidase-Like2 regulate endothelial ECM and angiogenesis through non-catalytic scaffolding mechanisms. Matrix Biology *88*, 33–52. 10.1016/j.matbio.2019.11.003.

68. Zaffryar-Eilot, S., Marshall, D., Voloshin, T., Bar-Zion, A., Spangler, R., Kessler, O., Ghermazien, H., Brekhman, V., Suss-Toby, E., Adam, D., et al. (2013). Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours. Carcinogenesis *34*, 2370–2379. 10.1093/carcin/bgt241.

69. Puxeddu, I., Pang, Y.Y., Harvey, A., Haitchi, H.M., Nicholas, B., Yoshisue, H., Ribatti, D., Clough, G., Powell, R.M., Murphy, G., et al. (2008). The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: Implications for airway remodeling in asthma. Journal of Allergy and Clinical Immunology *121*, 1400-1406.e4. 10.1016/j.jaci.2008.03.003.

70. Reichmann, M.T., Tezera, L.B., Vallejo, A.F., Vukmirovic, M., Xiao, R., Reynolds, J., Jogai, S., Wilson, S., Marshall, B., Jones, M.G., et al. Integrated transcriptomic analysis of human tuberculosis granulomas and a biomimetic model identifies therapeutic targets. J Clin Invest *131*, e148136. 10.1172/JCI148136.

71. Tekin, H., Simmons, S., Cummings, B., Gao, L., Adiconis, X., Hession, C.C., Ghoshal, A., Dionne, D., Choudhury, S.R., Yesilyurt, V., et al. (2018). Effects of 3D culturing conditions on the transcriptomic profile of stem-cell-derived neurons. Nat Biomed Eng *2*, 540–554. 10.1038/s41551-018-0219-9.

72. Schwartz, M.A., and Chen, C.S. (2013). Deconstructing Dimensionality. Science *339*, 402–404. 10.1126/science.1233814.

73. Junqueira, L.C., Bignolas, G., and Brentani, R.R. (1979). Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J *11*, 447–455. 10.1007/BF01002772.

74. Lattouf, R., Younes, R., Lutomski, D., Naaman, N., Godeau, G., Senni, K., and Changotade, S. (2014). Picrosirius Red Staining: A Useful Tool to Appraise Collagen Networks in Normal and Pathological Tissues. J Histochem Cytochem. *62*, 751–758. 10.1369/0022155414545787.

75. James, D.S., Brereton, C.J., Davies, D.E., Jones, M.G., and Campagnola, P.J. (2021). Examining lysyl oxidase-like modulation of collagen architecture in 3D spheroid models of idiopathic pulmonary fibrosis via second-harmonic generation microscopy. J Biomed Opt *26*, 066501. 10.1117/1.JBO.26.6.066501.

76. Sarrias, M.R., Gronlund, J., Padilla, O., Madsen, J., Holmskov, U., and Lozano, F. (2004). The Scavenger Receptor Cysteine-Rich (SRCR) Domain: An Ancient and Highly Conserved Protein Module of the Innate Immune System. CRI *24*. 10.1615/CritRevImmunol.v24.i1.10.

77. Lugassy, J., Zaffryar-Eilot, S., Soueid, S., Mordoviz, A., Smith, V., Kessler, O., and Neufeld, G. (2012). The Enzymatic Activity of Lysyl Oxidas-like-2 (LOXL2) Is Not Required for LOXL2-induced Inhibition of Keratinocyte Differentiation. J Biol Chem *287*, 3541–3549. 10.1074/jbc.M111.261016.

78. Soneson, C., Love, M.I., and Robinson, M.D. (2016). Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. Preprint at F1000Research, 10.12688/f1000research.7563.1 10.12688/f1000research.7563.1.

79. Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics *26*, 139–140. 10.1093/bioinformatics/btp616.

80. Hänzelmann, S., Castelo, R., and Guinney, J. (2013). GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics *14*, 7. 10.1186/1471-2105-14-7.

81. Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K. (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research *43*, e47–e47. 10.1093/nar/gkv007.

82. Naba, A., Clauser, K.R., Ding, H., Whittaker, C.A., Carr, S.A., and Hynes, R.O. (2016). The extracellular matrix: Tools and insights for the “omics” era. Matrix Biol *49*, 10–24. 10.1016/j.matbio.2015.06.003.

83. Booth, A.J., Hadley, R., Cornett, A.M., Dreffs, A.A., Matthes, S.A., Tsui, J.L., Weiss, K., Horowitz, J.C., Fiore, V.F., Barker, T.H., et al. (2012). Acellular Normal and Fibrotic Human Lung Matrices as a Culture System for In Vitro Investigation. Am J Respir Crit Care Med *186*, 866–876. 10.1164/rccm.201204-0754OC.

84. Szklarczyk, D., Morris, J.H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N.T., Roth, A., Bork, P., et al. (2017). The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible. Nucleic Acids Res *45*, D362–D368. 10.1093/nar/gkw937.

85. Yao, L., Conforti, F., Hill, C., Bell, J., Drawater, L., Li, J., Liu, D., Xiong, H., Alzetani, A., Chee, S.J., et al. (2019). Paracrine signalling during ZEB1-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in lung fibrosis. Cell Death Differ *26*, 943–957. 10.1038/s41418-018-0175-7.

86. Russell, H.K. (1972). A modification of Movat’s pentachrome stain. Arch Pathol *94*, 187–191.